Log in

Industry News

Kite’s Yescarta Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of R/R LBCL

On March 21, 2023, Kite announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of care (SOC) in a curative setting for nearly 30 years, for initial treatment in adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy. These findings will be presented in full later this year at an upcoming scientific meeting.

Please see full Prescribing Information, including BOXED WARNING and Medication Guide.

  • YESCARTA-220x56
  • Kite-186x56

Kite, the Kite logo, Yescarta, and GILEAD are trademarks of Gilead Sciences, Inc. or its related companies.
© 2017-2022 Gilead Sciences, Inc. All rights reserved.

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us